Xenical Related Published Studies
Well-designed clinical trials related to Xenical (Orlistat)
Orlistat and sibutramine beyond weight loss. [2008.06]
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. [2008.05]
Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity: A 16-Week Randomized, Double-Blind, Placebo-Controlled Trial. [2008.03.11]
Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial. [2007.12]
Rapid response predicts binge eating and weight loss in binge eating disorder: Findings from a controlled trial of orlistat with guided self-help cognitive behavioral therapy. [2007.11]
Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects. [2007.11]
Orlistat and sibutramine beyond weight loss. [2007.10.08]
Long-term persistence with orlistat and sibutramine in a population-based cohort. [2007.10]
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. [2007.08]
Rapid response predicts binge eating and weight loss in binge eating disorder: Findings from a controlled trial of orlistat with guided self-help cognitive behavioral therapy. [2007.06.07]
Long-term persistence with orlistat and sibutramine in a population-based cohort. [2007.04.10]
Orlistat reduces gallbladder emptying by inhibition of CCK release in response to a test meal. [2007.03.01]
Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome. [2007.02]
Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. [2006.10]
Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. [2006.10]
Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. [2006.10]
A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. [2006.05]
Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification? [2006.03]
Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. [2006.01]
Effect of orlistat in obese patients with binge eating disorder. [2005.10]
The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat. [2005.09]
Exercise training as an adjunct to orlistat therapy reduces oxidative stress in obese subjects. [2005.08]
Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. [2005.06.15]
Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. [2005.05.15]
Effect of Orlistat in obese patients with heart failure: a pilot study. [2005.05]
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. [2005.05]
Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size. [2005.05]
Effect of orlistat on cardiovascular disease risk in obese adults. [2005.05]
[Efficacy and safety of a short-time orlistat treatment in obese subjects] [2005.04]
Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. [2005.02]
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. [2005.01]
Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels. [2005.01]
Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. [2004.12]
Addition of orlistat to conventional treatment in adolescents with severe obesity. [2004.12]
A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. [2004.09.15]
The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. [2004.09]
Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. [2004.08]
Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. [2004.08]
Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations. [2004.06.01]
Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. [2004.05]
Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. [2004.04]
Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity. [2004.03.01]
Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? [2004.03]
The pathophysiology of faecal spotting in obese subjects during treatment with orlistat. [2004.02.01]
A systematic review of the clinical effectiveness of orlistat used for the management of obesity. [2004.02]
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. [2004.01]
Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. [2004.01]
Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. [2004.01]
Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. [2003.12]
Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal. [2003.12]
Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. [2003.11]
The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. [2003.10]
Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. [2003.05]
Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. [2003.05]
Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. [2003.05]
Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. [2003.04.15]
Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. [2003.04]
Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. [2003.04]
Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. [2003.01]
Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. [2002.11]
Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. [2002.11]
The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. [2002.11]
[Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study] [2002.09]
Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. [2002.09]
Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. [2002.09]
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. [2002.07]
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. [2002.06]
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. [2002.01]
The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. [2001.11]
Orlistat inhibits dietary cholesterol absorption. [2001.10]
Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. [2001.10]
Influence of orlistat on bone turnover and body composition. [2001.08]
Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). [2001.07]
Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. [2001.06]
Comparative evaluation of fecal fat excretion induced by orlistat and chitosan. [2001.06]
Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. [2001.06]
Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. [2001.04.01]
Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. [2000.12]
Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. [2000.10]
Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. [2000.09]
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. [2000.09]
Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. [2000.06]
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. [2000.05.08]
One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. [2000.03]
Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers. [2000.02]
Orlistat in the long-term treatment of obesity in primary care settings. [2000.02]
Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. [2000.01]
Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. [1999.09]
The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. [1999.09]
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. [1999.06]
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. [1999.01.20]
Treatment with orlistat reduces cardiovascular risk in obese patients. [1998.12]
The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. [1998.11]
Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. [1998.08]
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. [1998.07.18]
Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. [1998.04]
[Reduction of obesity and improvement in metabolic parameters by inhibition of intestinal lipases: current results with orlistat] [1998]
A one-year trial to assess the value of orlistat in the management of obesity. [1997.06]
Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. [1996.12]
The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. [1996.07]
The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. [1996.07]
|
